FEops combines predictive simulation and artificial intelligence for cardiac device design.
Materialise has acquired FEops, a Belgian company that develops AI-driven simulation technology to improve procedure efficiency and clinical outcomes for structural heart interventions. According to Materialise, the acquisition will enable the expansion of its cardiovascular solutions with predictive simulation capabilities.
The amount of the transaction was not disclosed.
FEops combines predictive simulation technology and artificial intelligence to improve the accuracy of predictions about how transcatheter structural heart devices will interact with a patient’s anatomy. Mimics Planner for Structural Heart Interventions, an industry-standard solution for segmentation and anatomical analysis, planning, and design, enables the creation of accurate virtual 3D models based on medical image data.
Materialise claims that the integration of FEops into the company’s existing Mimics Planner will offer a comprehensive solution for anatomy-based 3D planning and AI-based simulation, enabling users to simulate the interaction between a medical device, such as a heart valve, and a patient’s unique anatomy.
“At Materialise, we are pioneering the advent of mass personalization in healthcare, using advanced visualization and 3D printing technologies to deliver precise, patient-specific solutions,” said Brigitte de Vet, CEO of Materialise in a press release. “This integration will not only enhance the accuracy and efficiency of structural heart interventions but also improve clinical outcomes and patient safety.”
Structural heart diseases, like heart valve diseases, represent a significant medical and economic challenge, being the leading cause of cardiovascular morbidity and mortality worldwide. Currently, 47 million people suffer from heart valve diseases, and this number is steadily increasing. By 2030, the annual costs associated with adverse outcomes are projected to reach 70 billion USD globally.
Historically, transcatheter procedures were reserved for the most complex cases and high-risk patients, but these procedures are becoming more common today. However, challenges remain in evaluating patient eligibility for transcatheter interventions and assessing potential risks and adverse events.
Enhanced visualization and simulation technologies could improve the clinical workflow, thereby expanding the availability of transcatheter procedures to a broader range of patients and improving overall outcomes.
